Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board
· Financial Post
CAMBRIDGE, England -- Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Read More
Visit grenadier.co.za for more information.